Through efforts to develop a small molecule therapeutic targeting GPR61 for the treatment of cachexia, we have discovered a sulfonamide inverse agonist tool compound that exhibits potent and selective inhibition of GPR61 constitutive activity. This evidence concerns the gene GPR61 and Cachexia.